| 臺大學術典藏 |
2022-03-04T05:33:27Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; CHEN-TU WU; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-03-04T03:48:05Z |
Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer
|
Cho S.-L.; WEI-CHOU LIN; Chuang C.-A.; Liao W.-Y.; Lai C.-F. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients
|
Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:33Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
JIH-HSIANG LEE; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; Shih J.-Y.; Yu C.-J.; Chen K.-Y.; Tsai T.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:33Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; JIH-HSIANG LEE; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:30Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-14T07:10:40Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 國立成功大學 |
2022 |
Mesh-free simulation of two-phase fluid flow in porous media based on the shock-fitting method
|
Lee, E.-J.;Wang, Wang W.;Chen, P.;Jiao, Z.;Gong, Y.;Mu, D.;Liao, W.-Y. |
| 臺大學術典藏 |
2021-11-03T05:24:55Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; CHONG-JEN YU; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-11-03T05:24:54Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; CHONG-JEN YU; Chih-Hsin Yang J.; Shih J.-Y. |
| 臺大學術典藏 |
2021-11-03T02:33:02Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; Yu C.-J.; Chih-Hsin Yang J.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2021-11-03T02:33:02Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; JIN-YUAN SHIH; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-10-04T07:15:42Z |
Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study
|
Liao Y.-C.; Liao W.-Y.; Sun J.-L.; JEN-CHANG KO; Yu C.-J. |
| 臺大學術典藏 |
2021-10-04T07:15:41Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T05:58:15Z |
Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/ pharmacodynamic target in Asian ICU population: a prospective observational study
|
Wu C.-C.; CHIH-HSUN TAI; Liao W.-Y.; Wang C.-C.; Kuo C.-H.; Lin S.-W.; Ku S.-C. |
| 臺大學術典藏 |
2021-09-17T05:56:09Z |
Prospective evaluation of procalcitonin, soluble triggering receptor expressed on myeloid cells-1 and c-reactive protein in febrile patients with autoimmune diseases
|
Lin C.-H.; Hsieh S.-C.; LI-TA KENG; Lee H.-S.; Chang H.-T.; Liao W.-Y.; Ho C.-C.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:41:27Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; KAI-LUN YU; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2021-09-17T05:41:26Z |
The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer
|
KAI-LUN YU; Tsai T.-H.; Ho C.-C.; Liao W.-Y.; Lin C.-K.; Hsu C.-L.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:18Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
SHENG-KAI LIANG; Lee M.-R.; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:50:57Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-09T05:25:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
